Latest Breaking News On - Analyst recommendations for fusion pharmaceuticals - Page 1 : comparemela.com

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) have earned a consensus rating of “Hold” from the fourteen analysts that are presently covering the firm, MarketBeat reports. Thirteen equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month […]

New yorkUnited statesRaymond jamesWilliam blairLeerink partnrsRoyal bankFusion pharmaceuticals incFusion pharmaceuticalsFusion pharmaceuticals stock performanceInstitutional investors weigh in on fusion pharmaceuticalsChina universal asset management coYork state common retirement fundFusion pharmaceuticals company profileAnalyst recommendations for fusion pharmaceuticalsGamco investorsTower research capital